title: Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders.
abstract: OBJECTIVE
  To explore the association between eating disorders (EDs) prior to the use of clozapine/olanzapine (pre-clozapine/olanzapine EDs) and after initiation of these antipsychotics (post-clozapine/olanzapine EDs).
  
  
  METHODS
  Sixty-four consecutively admitted patients receiving clozapine/olanzapine were screened using the M-Composite International Diagnostic Interview (M-CIDI) to identify subjects with pre-clozapine/olanzapine EDs (DSM-IV criteria). We investigated post-clozapine/olanzapine EDs and binge eating behavior using the Questionnaire on Eating and Weight Patterns (QEWP) and used the Naranjo probability scale as objective causality assessment.
  
  
  RESULTS
  Post-clozapine/olanzapine EDs were significantly more frequent in patients with pre-clozapine/olanzapine EDs (5 of 6) when compared to patients without pre-clozapine/olanzapine EDs (4 of 58) [chi(2) = 26.29; df = 1; p < 0.001] [odds ratio (OR) 67.5; 95% CI: 6.3-725.8]. According to the Naranjo probability scale, recurrence or deterioration of EDs in patients with prior EDs was definitely (n = 1) or probably (n = 4) related to the intake of clozapine/olanzapine.
  
  
  CONCLUSIONS
  Clozapine/olanzapine may induce recurrence or deterioration of binge eating symptomatology or full-blown EDs in patients with prior EDs.
authors: Clinical Research Group, Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Germany.
authors: S
authors: S
authors: Gebhardt
authors: M
authors: M
authors: Haberhausen
authors: J-C
authors: JC
authors: Krieg
authors: H
authors: H
authors: Remschmidt
authors: M
authors: M
authors: Heinzel-Gutenbrunner
authors: J
authors: J
authors: Hebebrand
authors: F M
authors: FM
authors: Theisen
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001066:Appetite / Q000187:drug effects / Q000502:physiology; D001569:Benzodiazepines / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D052018:Bulimia Nervosa / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology*; D003024:Clozapine / Q000009:adverse effects*; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D000077152:Olanzapine; D012008:Recurrence; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine